|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.6200 - 1.7600|
|52 Week Range||0.4500 - 4.8200|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Mentor Capital, Inc. announced that during January it has funded an additional $900,000 into G FarmaLabs bringing the ten month multi-investment total by Mentor into G Farma to $1.8 million, which is in addition to an early and separate $600,000 stock transaction.
Mentor Capital, Inc. announced in a year-end note to shareholders that the corporation looks to immediately receive $2 million, successfully concluding its three-year litigation with Bhang Corporation.
Phoenix, AZ, Nov. 13, 2017-- Uppie Awards Nomination Results and Metrics. Friday November 3 rd, Uptick Newswire held the first annual Uppie Awards Show at The Flamingo in Las Vegas, Nevada. With over 30 ...
Mentor Capital, Inc. announced that it has filed its quarterly 10-Q filing for the third quarter ended September 30, 2017 with the Securities and Exchange Commission.
Mentor Capital, Inc. announced that it has filed its quarterly Form 10-Q filing for the second quarter ended June 30, 2017 with the Securities and Exchange Commission.
The Mentor Capital, Inc. team will be answering investor questions on the going public process at the G FarmaLabs booth at the NCIA Cannabis Business Summit and Expo June 12 – 14 in Oakland, CA.
Mentor Capital, Inc. announced that it has filed its quarterly 10-Q filing for the first quarter ended March 31, 2017 with the SEC.
Mentor Capital, Inc. is happy to announce that it has extended its funding to G FarmaLabs by an extra 20% with an additional loan on top of last month’s million dollar investment in this global cannabis leader founded under the vision, energy and genius of Ata Gonzalez.
Mentor Capital, Inc. is pleased to announce it has again provided $100,000 in special project financing for cannabis advisory leader Electrum Partners, LLC. “Since our first $100,000 round of Electrum funding in March 2014, the Mentor team has gained great confidence in the business model developed by Leslie Bocskor, who now sits on the board of directors of GB Sciences and Grow Solutions Holdings ...
Mentor Capital, Inc. announces that early shareholders who together also hold approximately 3,000,000 Series B Warrants are having the 10 cent per warrant redemption payment for those warrants voluntarily paid out now by the Company approximately one-year in advance of the May 1, 2018 date previously scheduled with the Depository Trust & Clearing Corporation .
Mentor Capital, Inc. announces it has initiated funding for its GlauCanna venture for the use of medical marijuana in the treatment of glaucoma patients. Mentor will provide funding and business management for any commercial development and holds an 80% interest.
Mentor Capital, Inc. announced it has continued adding over 1,000 shareholders per month bringing its base of active shareholders who have Mentor shares in a brokerage account to 10,000 from 6,000 just at year end and 3,000 only three months earlier.
Mentor Capital, Inc. announced that it has filed its annual 10-K filing for the year ended December 31, 2016 with the SEC.
Mentor Capital, Inc. announces it has closed and paid in cash and stock a $1.0 million multi-faceted financing program for G FarmaLabs Limited. The initial Mentor financing is structured to provide funding for real estate and working capital.
Mentor Capital, Inc. is now closing a long chapter in its history and estimates that has completely recovered $15 million for those 1,200 shareholders that Mentor uncovered had been defrauded by private syndicators before they became Mentor shareholders.
Mentor Capital, Inc. CEO Chet Billingsley reported that since August 15, 2016 he has contractually limited his stock sale orders to a level 13,500 to 16,000 shares in any given week and the Mentor share price rose 600%.
Mentor Capital, Inc. met with Congressman Dana Rohrabacher of Newport Beach at his reception by the Cannabis Host Committee in San Diego, March 6th, 2017. Mentor CEO Chet Billingsley, nicknamed “The Doc” by the Congressman, outlined in discussion how 20% of the opiate crises and 6,000 annual deaths could be avoided by the projected 20% substitution to legal cannabis from other illegal drugs that would ...
Mentor Capital, Inc. announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc , a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.
Mentor Capital, Inc. announced it has doubled its base of active shareholders who have shares in a brokerage account in the last quarter rising 100% to 6,000 from 3,000 three months earlier.